Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to shift the market?

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

NCT05564117), a 64-week study that included a 12-week dose escalation and a 7-week off-treatment follow-up period. Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n ...